



# ANNUAL ONCOAGE MEETING

**Immunotherapy/targeted  
therapy and OncoAge :  
What is news ?**

**18 - 19 NOVEMBER, 2021  
LE SAINT PAUL, NICE**



UNDER THE HIGH PATRONAGE OF  
LA LIGUE CONTRE LE CANCER



ORGANIZED WITH THE COMMUNITIES OF  
THE C.I.U.S. | HEALTHCARE INNOVATION LAB



SUPPORTED BY



## **THURSDAY 18 NOVEMBER**

### **Session 1**

**8:30 AM-12h30 AM.  
Head and Neck  
Carcinoma/Melanoma**

### **Session 2**

**2:00 PM-5:00 PM.  
Lung cancer (1)**

## **FRIDAY 19 NOVEMBER**

### **Session 3**

**09:00 AM-12:00 AM.  
Lung cancer (2)**

### **Session 4**

**02:00 PM-4:30 PM.  
Lung cancer (3)**

 29 Bd Franck Pilatte, 06300 Nice  
 [hofman.p@chu-nice.fr](mailto:hofman.p@chu-nice.fr)  
[skhiri.t@chu-nice.fr](mailto:skhiri.t@chu-nice.fr)

## **SESSION 1 : THURSDAY 18 NOVEMBER**

- 08:30–09:00 AM *Welcome and update in OncoAge*  
**Paul Hofman**, OncoAge, IRCAN, Côte d'azur University, Nice  
France
- 09:00–09:30 AM *Treatment of elderly recurrent/metastatic head and neck cancer patients in the immunotherapy era*  
**Joel Guigay**, OncoAge, Antoine Lacassagne Comprehensive Cancer Center, Nice, France
- 09:30–10:00 AM *Insights on spe(a)cial features of the extracellular matrix that impact solid tumor growth and therapy resistance*  
**Ellen van Obberghen**, OncoAge, IBV, Côte d'Azur University, Nice, France
- 10:00–10:30 AM *Baseline and early functional immune response and clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients*  
**Thierry Passeron**, OncoAge, C3M, Côte d'Azur University, Nice, France
- 10:30–11:00 AM *Update of immunotherapy in head and neck cancer*  
**Jérôme Fayette**, OncoAge, Léon Bérard Comprehensive Cancer Center, Lyon, France
- 11:00–11:30 AM *Molecular and immunesubtypes of oral squamous cell carcinomas*  
**Pierre Saintigny**, OncoAge, Léon Bérard Comprehensive Cancer Center, Lyon, France
- 11:30–12:00 AM *Targeting fibrotic-like response induced by targeted therapies in melanoma*  
**Sophie Tartare**, OncoAge, C3M, Côte d'Azur University, Nice, France
- 12:00–12:30 PM *New compounds that exert anti-melanoma effects through induction of Endoplasmic Reticulum stress*  
**Stéphane Rocchi**, OncoAge, C3M, Côte d'Azur University, Nice, France

**12:30 -2:00 PM Lunch**



## **SESSION 2 : THURSDAY 18 NOVEMBER**

- 2:00–2:30 PM *Should we treat older patients with immunotherapy-chemotherapy combo for non-small-cell lung metastatic cancer?*  
**Maxime Frelaut**, Institut Gustave Roussy, Villejuif, France
- 2:30–3:00 PM *Non-invasive analysis of immune biomarkers for early detection of tumor escape to immunotherapy in lung cancer*  
**Marius Ilie**, OncoAge, IRCAN, Côte d'azur University, Nice France
- 3:00–3:30 PM *Noninvasive imaging of immune responses*  
**Léa Berland**, OncoAge, IRCAN & Dana Farber Cancer Institut, Boston, USA
- 3:30–4:00 PM *Whole genome methylation analysis of LS-SCLC samples reveals distinct subtype-specific patterns*  
**Simon Heeke**, OncoAge, IRCAN & MD Anderson Cancer Center, USA
- 4:00–5:00 PM *Homologous repair deficiency (HRD)*  
**Albrecht Stenzinger**, Institut of Pathology, University Hospital Heidelberg, Germany
- 5:00–6:00 PM *Status of biomarker testing in Europe*  
**Nicola Normanno**, Head of the Experimental Therapy Section INT Fondazione Pascale, Napoli, Italy
- 6:00–6:45 PM *Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions*  
**Geoffrey R Oxnard**, Department of Medical Oncology, Boston Medical Center and Boston University, Boston, USA
- 

## **SESSION 3 : FRIDAY 19 NOVEMBER**

- 09:00–09:30 AM *Research on prevention and treatment of NSCLC: A new academic approach*  
**Benjamin Besse**, Institut Gustave Roussy, Villejuif, France
- 09:30–10:00 AM *Building a rationale for immunoprevention strategies*  
**Jebrane Bouaoud**, OncoAge, Léon Bérard Comprehensive Cancer Center, Lyon, France
- 10:00–10:30 AM *Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer*  
**Laeticia Seguin**, OncoAge, IRCAN, Côte d'Azur University, Nice, France
- 10:30–11:00 AM *Cooperative TET2 Loss and KRAS Mutation accelerates non-small cell lung cancer and Nlrp3 inhibitor sensitivity*  
**Laurent Yvan-Charvet**, OncoAge, C3M, Côte d'Azur University, Nice, France
- 11:00–11:30 AM *Non coding RNA, hypoxia and drug resistance in lung cancer*  
**Bernard Mari**, OncoAge, IPMC, Côte d'Azur University, Nice, France
- 11:30–12:00 AM *Mitophagy regulation in lung cancer*  
**Jean-Erland Ricci**, OncoAge, C3M, Côte d'Azur University, Nice, France

**12:00 -2:00 PM Lunch**



## **SESSION 4 : FRIDAY 19 NOVEMBER**

- 2:00–2:30 PM *Profiling drug-tolerant persister cells in lung cancer, using predictive single-cell dynamics*  
**Jérémie Roux**, OncoAge, IRCAN, Côte d'Azur University, Nice, France
- 2:30–3:00 PM *Targeting human endogenous retroviruses for lung cancer immunotherapy*  
**Baharia Mograbi**, OncoAge, IRCAN, Côte d'azur University, Nice, France
- 3:00–3:30 PM *Targeting sequencing and NGS in early stage of lung cancer : Do both are still viable ?*  
**Paul Hofman**, OncoAge, IRCAN, Côte d'azur University, Nice, France
- 3:30–4:00 PM *RNA granules and lung cancer progression*  
**Patrick Brest**, OncoAge, IRCAN, Côte d'azur University, Nice, France
- 4:00–4:30 PM **Conclusions and closing cocktail**

